115 related articles for article (PubMed ID: 32448508)
1. LXR activation radiosensitizes non-small cell lung cancer by restricting myeloid-derived suppressor cells.
Liang H; Shen X
Biochem Biophys Res Commun; 2020 Jul; 528(2):330-335. PubMed ID: 32448508
[TBL] [Abstract][Full Text] [Related]
2. LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer.
Tavazoie MF; Pollack I; Tanqueco R; Ostendorf BN; Reis BS; Gonsalves FC; Kurth I; Andreu-Agullo C; Derbyshire ML; Posada J; Takeda S; Tafreshian KN; Rowinsky E; Szarek M; Waltzman RJ; Mcmillan EA; Zhao C; Mita M; Mita A; Chmielowski B; Postow MA; Ribas A; Mucida D; Tavazoie SF
Cell; 2018 Feb; 172(4):825-840.e18. PubMed ID: 29336888
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non-Small Cell Lung Cancer.
Li R; Salehi-Rad R; Crosson W; Momcilovic M; Lim RJ; Ong SL; Huang ZL; Zhang T; Abascal J; Dumitras C; Jing Z; Park SJ; Krysan K; Shackelford DB; Tran LM; Liu B; Dubinett SM
Cancer Res; 2021 Jun; 81(12):3295-3308. PubMed ID: 33853830
[TBL] [Abstract][Full Text] [Related]
4. SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer.
Tao Z; McCall NS; Wiedemann N; Vuagniaux G; Yuan Z; Lu B
Clin Cancer Res; 2019 Feb; 25(3):1113-1124. PubMed ID: 30352911
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways.
Sawant A; Schafer CC; Jin TH; Zmijewski J; Tse HM; Roth J; Sun Z; Siegal GP; Thannickal VJ; Grant SC; Ponnazhagan S; Deshane JS
Cancer Res; 2013 Nov; 73(22):6609-20. PubMed ID: 24085788
[TBL] [Abstract][Full Text] [Related]
6. Liver X receptor agonist GW3965 protects against sepsis by promoting myeloid derived suppressor cells apoptosis in mice.
Zhang W; Luo M; Zhou Y; Hu J; Li C; Liu K; Liu M; Zhu Y; Chen H; Zhang H
Life Sci; 2021 Jul; 276():119434. PubMed ID: 33785343
[TBL] [Abstract][Full Text] [Related]
7. Immunoregulation and Clinical Implications of ANGPT2/TIE2
Lauret Marie Joseph E; Laheurte C; Jary M; Boullerot L; Asgarov K; Gravelin E; Bouard A; Rangan L; Dosset M; Borg C; Adotévi O
Cancer Immunol Res; 2020 Feb; 8(2):268-279. PubMed ID: 31871121
[TBL] [Abstract][Full Text] [Related]
8. CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer.
Zhang M; Yang W; Wang P; Deng Y; Dong YT; Liu FF; Huang R; Zhang P; Duan YQ; Liu XD; Lin D; Chu Q; Zhong B
Nat Commun; 2020 Nov; 11(1):6119. PubMed ID: 33257678
[TBL] [Abstract][Full Text] [Related]
9. Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients.
Heuvers ME; Muskens F; Bezemer K; Lambers M; Dingemans AC; Groen HJM; Smit EF; Hoogsteden HC; Hegmans JPJJ; Aerts JGJV
Lung Cancer; 2013 Sep; 81(3):468-474. PubMed ID: 23850196
[TBL] [Abstract][Full Text] [Related]
10. Levels of peripheral blood polymorphonuclear myeloid-derived suppressor cells and selected cytokines are potentially prognostic of disease progression for patients with non-small cell lung cancer.
Barrera L; Montes-Servín E; Hernandez-Martinez JM; Orozco-Morales M; Montes-Servín E; Michel-Tello D; Morales-Flores RA; Flores-Estrada D; Arrieta O
Cancer Immunol Immunother; 2018 Sep; 67(9):1393-1406. PubMed ID: 29974189
[TBL] [Abstract][Full Text] [Related]
11. Prognostic role of liver X receptor-alpha in resected stage II and III non-small-cell lung cancer.
Melloni G; Muriana P; Bandiera A; Fontana R; Maggioni D; Russo V; Doglioni C; Zannini P
Clin Respir J; 2018 Jan; 12(1):241-246. PubMed ID: 27401614
[TBL] [Abstract][Full Text] [Related]
12. Yeast-Derived Particulate β-Glucan Treatment Subverts the Suppression of Myeloid-Derived Suppressor Cells (MDSC) by Inducing Polymorphonuclear MDSC Apoptosis and Monocytic MDSC Differentiation to APC in Cancer.
Albeituni SH; Ding C; Liu M; Hu X; Luo F; Kloecker G; Bousamra M; Zhang HG; Yan J
J Immunol; 2016 Mar; 196(5):2167-80. PubMed ID: 26810222
[TBL] [Abstract][Full Text] [Related]
13. Reduction of fibrosis and immune suppressive cells in ErbB2-dependent tumorigenesis by an LXR agonist.
Sheng G; Yuan H; Jin L; Ranjit S; Panov J; Lu X; Levi M; Glazer RI
PLoS One; 2021; 16(3):e0248996. PubMed ID: 33780491
[TBL] [Abstract][Full Text] [Related]
14. Myeloid-Derived Suppressor Cells Are a Major Source of Wnt5A in the Melanoma Microenvironment and Depend on Wnt5A for Full Suppressive Activity.
Douglass SM; Fane ME; Sanseviero E; Ecker BL; Kugel CH; Behera R; Kumar V; Tcyganov EN; Yin X; Liu Q; Chhabra Y; Alicea GM; Kuruvilla R; Gabrilovich DI; Weeraratna AT
Cancer Res; 2021 Feb; 81(3):658-670. PubMed ID: 33262126
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy activates autophagy to increase CD8
Zeng H; Zhang W; Gong Y; Xie C
J Int Med Res; 2019 Aug; 47(8):3818-3830. PubMed ID: 31187666
[TBL] [Abstract][Full Text] [Related]
17. Silymarin suppressed lung cancer growth in mice via inhibiting myeloid-derived suppressor cells.
Wu T; Liu W; Guo W; Zhu X
Biomed Pharmacother; 2016 Jul; 81():460-467. PubMed ID: 27261626
[TBL] [Abstract][Full Text] [Related]
18. Thymosin alpha-1 blocks the accumulation of myeloid suppressor cells in NSCLC by inhibiting VEGF production.
Yang Z; Guo J; Cui K; Du Y; Zhao H; Zhu L; Weng L; Tang W; Guo J; Zhang T; Shi X; Zong H; Jin S; Ma W
Biomed Pharmacother; 2020 Nov; 131():110740. PubMed ID: 32942159
[TBL] [Abstract][Full Text] [Related]
19. Sequential depletion of myeloid-derived suppressor cells and tumor cells with a dual-pH-sensitive conjugated micelle system for cancer chemoimmunotherapy.
Wan D; Yang Y; Liu Y; Cun X; Li M; Xu S; Zhao W; Xiang Y; Qiu Y; Yu Q; Tang X; Zhang Z; He Q
J Control Release; 2020 Jan; 317():43-56. PubMed ID: 31758970
[TBL] [Abstract][Full Text] [Related]
20. Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model.
Metzger P; Kirchleitner SV; Boehmer DFR; Hörth C; Eisele A; Ormanns S; Gunzer M; Lech M; Lauber K; Endres S; Duewell P; Schnurr M; König LM
Cancer Immunol Immunother; 2020 Oct; 69(10):2101-2112. PubMed ID: 32448983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
